GlassScriptPhysician profile
David R Liljenquist
NPI 1932109931
$9,203.02
in general payments reported to CMS, 2019-2025
67 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,492 · 2020: $1,413 · 2021: $1,345 · 2022: $1,559 · 2023: $1,080 · 2024: $1,188 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,117 · Education: $245 · Entertainment: $30.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,117.48 |
| Education | $244.50 |
| Entertainment | $30.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $796.13 | 2019-2025 | |
| Novo Nordisk INC | $773.83 | 2019-2025 | Wegovy, Sogroya |
| Lilly USA, LLC | $631.64 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $586.67 | 2019-2025 | Tepezza, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.89 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $543.86 | 2019-2025 | |
| Radius Health, INC. | $513.30 | 2019-2024 | Tymlos |
| Abbott Laboratories | $411.61 | 2020-2025 | Freestyle Libre 3 |
| Insulet Corporation | $270.51 | 2020-2024 | Omnipod |
| Corcept Therapeutics | $256.19 | 2020-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $255.73 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $242.54 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $238.09 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $231.25 | 2019-2023 | Lokelma |
| Madrigal Pharmaceuticals | $226.45 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $214.46 | 2021-2025 | |
| Amarin Pharma, INC. | $179.96 | 2020-2021 | |
| Ibsa Pharma INC. | $171.37 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $167.27 | 2022-2025 | Yorvipath, Skytrofa |
| Regeneron Healthcare Solutions, INC. | $151.35 | 2019-2025 | Evkeeza |
| Recordati_rare_diseases_inc. | $108.76 | 2021-2025 | Isturisa, Signifor Lar |
| Chiesi USA, INC. | $105.46 | 2025 | Mycapssa |
| Kyowa Kirin, INC. | $103.91 | 2023-2025 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $101.69 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $74.61 | 2024-2025 | |
| Pfizer INC. | $73.87 | 2022-2023 | |
| Allergan, INC. | $72.26 | 2020 | |
| Amryt Pharma Holdings LTD | $67.02 | 2020-2023 | Myalept |
| Dexcom, INC. | $66.48 | 2022-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $60.37 | 2023-2025 | Inspire |
| Horizon Therapeutics Plc | $60.19 | 2021-2023 | Tepezza |
| Medtronic Vascular, INC. | $59.61 | 2020 | |
| Tandem Diabetes Care, INC. | $54.51 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Nestle Healthcare Nutrition INC. | $54.36 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $52.71 | 2021-2022 | |
| Senseonics, Incorporated | $50.00 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $48.50 | 2022-2025 | Imcivree |
| Medtronic, INC. | $41.31 | 2021-2024 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $40.67 | 2019 | |
| Strongbridge US INC. | $39.43 | 2019-2020 | |
| Averitas Pharma INC. | $36.94 | 2025 | Qutenza |
| Tolmar, INC. | $36.07 | 2023-2025 | Fensolvi |
| Optos, INC. | $30.83 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Ferring Pharmaceuticals INC. | $29.31 | 2019 | |
| Nevro Corp. | $28.88 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $26.59 | 2023-2024 | Quviviq |
| Chiasma, INC. | $26.15 | 2021 | |
| Arbor Pharmaceuticals, INC. | $24.43 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $19.92 | 2022 | |
| Eton Pharmaceuticals, INC. | $18.67 | 2024 | Alkindi |
| Beta Bionics, INC. | $17.10 | 2024 | Ilet Bionic Pancreas |
| Curonix LLC | $16.61 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biomarin Pharmaceutical INC. | $16.46 | 2024 | Voxzogo 1.2mg |
| Antares Pharma, INC. | $15.13 | 2019 | |
| Eusa Pharma (US) LLC | $14.87 | 2022 | |
| Grt US Holding, INC. | $14.20 | 2022 | |
| Halozyme INC | $14.10 | 2023 | |
| Boston Scientific Corporation | $14.02 | 2025 | General - Pain Management |
| Medtronic Minimed, INC. | $12.93 | 2019 | |
| Esperion Therapeutics, INC. | $12.12 | 2021 | |
| Aegerion Pharmaceuticals, INC. | $10.95 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.92 | 2025 | Voquezna |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Liljenquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.